Dysport® Clostridium Botulinum Type A from New Zealand Medical and Scientific Ltd

  • Dysport® Clostridium Botulinum Type A

Description

Dysport is a simple, effective, non-surgical treatment that works by relaxing facial muscles on the forehead, thereby reducing and smoothing away frown-lines and wrinkles.

Dysport is supported by over a decade of clinical experience. Dysport was developed in the United Kingdom in the early 1990s to successfully treat a number of neurological and ophthalmic conditions. Since that time, with an increased understanding of the uses of Dysport, thousands of treatments have been safely and effectively performed for a variety of conditions ranging from frown lines to axillary hyperhidrosis (excessive sweating under the armpits).

  • Product Specs
  • ItemDysport® Clostridium Botulinum Type A
  • CompanyNew Zealand Medical and Scientific Ltd
  • Price Inquire
  • ApprovalIn New Zealand, Dysport now has registration approval under the Medicines Act for the treatment of frown lines and for excessive sweating under the armpits.
  • Product NumberInquire
  • StorageThe shelf life of the packaged product is 12 months when stored at 2-8°C. Maximum storage time of reconstituted product is 8 hours at 2-8°C.
  • IndicationsCervical dystonia, cerebral palsy in children, blepharospasm/hemifacial spasm, hyperhidrosis and glabellar lines.
  • Mechanism of ActionThe active substance in Dysport® is a botulinum neurotoxin type A complex, which acts at the level of the neuromuscular junction in the targeted muscle.
  • PackagingInquire
  • Units/Vial500 Units
  • Suggested ReconstitutionWhen treating glabellar lines, Dysport is reconstituted with 2.5ml of sodium chloride injection BP (0.9%) to yield a solution containing 10 units of Dysport per 0.05 ml. Dysport is administered by intramuscular or subcutaneous injection.

    Dysport is reconstituted with 1.0ml of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per ml of Dysport. Dysport is administered by intramuscular injection into the five muscles detailed above when treating arm spasticity.

    When treating paediatric cerebral palsy spasticity, Dysport is reconstituted with 1.0ml of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per ml of Dysport. Dysport is administered by intramuscular injection into the calf muscles when treating spasticity.

    When treating spasmodic torticollis Dysport is reconstituted with 1ml of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per ml of Dysport. Dysport is administered by intramuscular injection as above when treating spasmodic torticollis.

    When treating blepharospasm and hemifacial spasm Dysport is reconstituted with 2.5ml of sodium chloride injection BP (0.9%) to yield a solution containing 200 units per ml of Dysport. Dysport is administered by subcutaneous injection medially and laterally into the junction between the preseptal and orbital parts of both the upper and lower orbicularis oculi muscles of the eyes.

    When treating axillary hyperhidrosis, Dysport is reconstituted with 2.5ml of sodium chloride solution (0.9%) to yield a solution containing 200 units per ml of Dysport.

Add to Compare List